GlassScriptPhysician profile
Martin Q Tran
NPI 1851395891
$8,596.69
in general payments reported to CMS, 2019-2025
32 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $564 · 2021: $912 · 2022: $1,485 · 2023: $1,580 · 2024: $1,876 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,023 · Education: $82.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,022.93 |
| Education | $82.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,111.60 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $762.81 | 2020-2025 | Terlivaz, Acthar |
| Amgen INC. | $684.85 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $683.51 | 2021-2025 | |
| Travere Therapeutics, INC. | $596.03 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $525.21 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $496.78 | 2019-2025 | Ultomiris, Soliris |
| Akebia Therapeutics INC | $483.13 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $468.31 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $361.48 | 2023-2025 | |
| Daiichi Sankyo INC. | $345.47 | 2019-2024 | Injectafer |
| Horizon Therapeutics Plc | $327.83 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $305.14 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $250.62 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $237.61 | 2020-2023 | Jesduvroq, Benlysta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $234.50 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $227.30 | 2019-2023 | Veltassa |
| Lilly USA, LLC | $143.13 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $54.37 | 2024-2025 | Rivfloza, Wegovy, Ozempic |
| Ardelyx, INC. | $40.71 | 2024-2025 | Ibsrela |
| Kyowa Kirin, INC. | $36.36 | 2022-2023 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $33.24 | 2024-2025 | Gattex |
| Apellis Pharmaceuticals, INC. | $22.90 | 2025 | Empaveli |
| Corcept Therapeutics | $22.61 | 2024 | Korlym |
| Scpharmaceuticals INC. | $22.56 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.23 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $20.30 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $18.21 | 2023 | Envarsus |
| Genzyme Corporation | $17.91 | 2019 | |
| Shield Therapeutics INC | $14.59 | 2025 | |
| Shire North American Group INC | $13.42 | 2019 | |
| Pharmacosmos Therapeutics INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.